SerpApi.Org
The proposal would add annual testing for service members 30 and older, with voluntary testing for younger troops. Critics are asking whether the Pentagon is following medicine, politics or both.
Democratic senators want answers about Pete Hegseth’s military testosterone plan after the defense secretary announced Wednesday in Washington a new screening program for testosterone deficiency among U.S. military troops. The policy would test service members 30 and older during annual medical screenings, let troops under 30 volunteer for testing and offer voluntary hormone replacement therapy.
The article explains what Hegseth’s policy would do and why Democrats are questioning it now: the plan touches military readiness, medical evidence, gender fairness and a politically charged debate over hormones inside the Pentagon.
What Hegseth announced
Hegseth described the program as a readiness measure, saying troops should be able to perform at their absolute best. According to the Associated Press, he said the screenings would become part of required annual medical checks for service members age 30 and older, while younger troops could opt in.
He also said testosterone replacement therapy would be voluntary, not mandatory. That distinction matters because hormone therapy is a medical treatment with possible benefits for some patients and limits that doctors usually evaluate case by case.
Hegseth framed the program around strength, resilience and battlefield demands. The Pentagon, when asked by the AP what medical conditions the policy was meant to address, pointed back to Hegseth’s remarks about psychological and mental readiness.
One ambiguity is already drawing attention: Hegseth referred broadly to troops, but the proposal appears to focus on men in uniform and testosterone irregularities. The Pentagon did not clarify whether women would have comparable access to hormone-related screening tied to menopause or perimenopause.
Why Democrats are pushing back
Democratic concern is partly about process. A military-wide screening program can affect privacy, medical workloads, standards of care and how commanders understand a service member’s health status. Lawmakers want to know what evidence the Pentagon is relying on before adding the test to routine care.
It is also about consistency. Sen. Tammy Duckworth, an Illinois Democrat and Iraq War veteran, criticized the announcement by saying it sounded like gender-affirming care, a pointed reference to Hegseth’s opposition to transgender troops. Rep. Chrissy Houlahan, a Pennsylvania Democrat and Air Force veteran, said the policy reflected influence from the far corners of the manosphere.
Both Duckworth and Houlahan called for hormone screening to be available to both men and women, according to the AP. That argument shifts the fight from whether testosterone should be tested to whether the Pentagon is building a medically neutral program or one shaped around a narrow idea of male performance.
For Democrats, the unanswered questions are practical as much as political: Who qualifies for treatment? What symptoms must be present? How will abnormal results be confirmed? What happens if a service member declines treatment after being screened?
The medicine is more complicated
Testosterone levels in men tend to decline with age, and low levels can be linked to erectile dysfunction, low libido, mood changes and weight gain. But medical experts have long debated how broadly to test for low testosterone and when replacement therapy is appropriate.
Current medical guidelines generally do not recommend blanket testosterone testing for everyone. Doctors are typically advised to consider therapy for men who have troubling symptoms and documented low hormone levels, often confirmed by two separate blood tests.
Testing itself is not simple. Testosterone levels fluctuate throughout the day, and more accurate readings are usually taken in the morning after fasting. A single low reading may not tell the full story.
There is evidence of benefit in specific groups. National Institutes of Health studies in older men found testosterone improved sexual measures such as libido and erectile dysfunction and had a small effect on mood. But those studies found little or no improvement in fatigue, memory or overall well-being, and that distinction matters when the Pentagon frames the policy around broad readiness.
Readiness or performance enhancement
Hegseth said the plan is not about artificial enhancement. That line is important because the military has already faced scrutiny over testosterone and related substances, especially in elite units.
After the 2022 death of a Navy SEAL recruit during training, the discovery of substances including testosterone helped expose wider drug-use concerns in the elite program. A year later, the Navy said it would begin testing for hormonal substances related to testosterone that promote muscle growth.
That history makes the new proposal sensitive. A medically supervised screening program is different from illicit performance-enhancing drug use. But critics will likely ask how the Pentagon plans to prevent a readiness program from becoming a pathway to normalizing hormone use for marginal performance gains.
Supporters of the plan may argue that diagnosing a real deficiency is no different from treating any other medical condition that affects deployability. The harder question is whether the Pentagon can draw a credible line between treating illness and chasing optimization.
A wider Trump administration push
The timing also feeds the scrutiny. Hegseth’s announcement comes as Trump administration health officials have shown interest in making testosterone easier to prescribe. Health Secretary Robert F. Kennedy Jr. and other officials have supported broader access, and the Food and Drug Administration recently proposed easing prescribing limits on testosterone gels, pills, patches and injections.
The current FDA labeling has treated testosterone medications as intended for men with hypogonadism, a condition that causes drastically low testosterone. At the same time, testosterone has become a popular theme among wellness influencers who promote it as a tool for youthfulness, muscle gain and mental sharpness.
Some safety concerns have eased. The FDA last year removed a boxed warning about possible heart attack and stroke risks from testosterone drugs. Still, that does not settle whether large-scale screening in a younger, active-duty military population is the right approach.
The political backdrop is hard to ignore. A hormone policy aimed at male troops lands differently when the Pentagon is also debating gender, fitness standards and who belongs in uniform. That is why Democrats are treating the announcement as more than a medical memo.
What remains unanswered
The Pentagon has not publicly provided the research base behind the program, according to the AP. It also has not said whether female troops would be evaluated for estrogen-based therapy as they enter perimenopause, or whether the new screening will be implemented uniformly across the services.
There are operational questions too. Annual medical screenings already serve many purposes, from deployability assessments to preventive care. Adding hormone testing could require new lab capacity, follow-up appointments, prescribing protocols and privacy safeguards.
The stakes are bigger than one blood test. If the Pentagon can show the plan is evidence-based, voluntary and equally attentive to men’s and women’s health needs, it may defend the policy as a readiness upgrade. If it cannot, Democrats will have a clear opening to portray the plan as ideology dressed up as medicine.
For now, Hegseth has put testosterone screening on the military policy agenda. The next fight is over whether the Pentagon can explain exactly what problem it is solving, and for whom.
